Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

60.34
-0.0250-0.04%
Volume:661.05K
Turnover:39.95M
Market Cap:10.03B
PE:-17.34
High:60.99
Open:60.37
Low:60.19
Close:60.36
52wk High:86.74
52wk Low:49.13
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.43
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:22.80
PE(LYR):-25.34

Loading ...

S&P 500 Futures Climb in Premarket Trading; Alnylam Pharmaceuticals, Bridgebio Pharma Lead

Dow Jones
·
Jul 09

Schwab Strategists Warn of a Major Market Shift: the Era of Easy Index Gains is Officially Over.

Dow Jones
·
Jul 09

Major Drugmaker Loses $27 Billion in Market Value After Failed Trial

Dow Jones
·
Jul 09

AstraZeneca says CARDIO-TTRansform trial did not meet primary efficacy endpoint

TIPRANKS
·
Jul 09

Tech Rebound Lifts European Shares After Three-day Slide

Reuters
·
Jul 09

Ionis Pharmaceuticals Shares Fall 13.8% Premarket After Drug Made in Partnership with Astrazeneca Fails Late-stage Heart Disease Trial

THOMSON REUTERS
·
Jul 09

Movement Alert|Ionis Pharmaceuticals Falls 14.75% in Pre-Market Trading, Phase 3 ATTR-CM Trial for Eplontersen Fails Primary Endpoint

Market Focus
·
Jul 09

Astrazeneca Top Loser on FTSE 100 After Heart Disease Drug Fails Late-stage Trial

Reuters
·
Jul 09

Astrazeneca Shares Set for Their Biggest One-day Fall Since March 2020

THOMSON REUTERS
·
Jul 09

Astrazeneca Shares Down 9% After Late-stage Trial Miss for Nerve Disease Drug Wainua

THOMSON REUTERS
·
Jul 09

European Shares Gain as Tech Stocks Rebound; Middle East in Focus

Reuters
·
Jul 09

Astrazeneca's Wainua Fails Key Heart Disease Trial, Shares Tumble

Reuters
·
Jul 09

Ionis Says Phase 3 Eplontersen Trial in Attr-cm Misses Primary Endpoint

Reuters
·
Jul 09

Update on Cardio-ttransform Phase 3 Trial of Eplontersen in Adults with Transthyretin-mediated Amyloid Cardiomyopathy

THOMSON REUTERS
·
Jul 09

Ionis Pharmaceuticals - Cardio-ttransform Phase 3 Trial for Eplontersen Misses Primary Endpoint up to Week 140

THOMSON REUTERS
·
Jul 09

Ionis Director Joseph Klein III Disposes of $910,231.42 in Common Shares

Reuters
·
Jul 07

Ionis Pharmaceuticals (IONS) Could Be 19% Undervalued After REVEAL Study Enrollment Milestone

Simply Wall St.
·
Jul 07

Ionis Completes Enrollment in Pivotal Phase 3 Reveal Cohort for Angelman Drug Obudanersen

Reuters
·
Jul 06

Ionis Pharmaceuticals - to Initiate Phase 3 Champion Study of Obudanersen Before End of 2026

THOMSON REUTERS
·
Jul 06

Ionis Pharmaceuticals - Topline Data from Reveal Study Expected in Second Half of 2027

THOMSON REUTERS
·
Jul 06